Pharmacies warn of unsustainable demand for weight loss medication
Many more patients are interested in using weight loss medication than are actually suitable for treatment, according to the National Pharmacy Association (NPA), which represents more than 6,000 independent community pharmacies.
Some 21% of people who were interviewed in a NPA-commissioned poll agreed they had attempted to access weight loss treatments in the last year, either online or in person at a pharmacy, rising to 35% of 16 to 34-year-olds.
This is compared to only 7% of those over 55.
There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them.
This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible.
The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services.
NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it.
'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment.
'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.'
Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear.
Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour.
Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS.
Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight.
The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says.
The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed.
They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme.
At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates.
Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice.
'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
AstraZeneca CFO talks tariffs & shifting focus to US market
AstraZeneca's (AZN) revenue hit a record high in the second quarter, driven by cancer drug sales and growth in the US market. AstraZeneca CFO Aradhana Sarin sits down with Market Catalysts host Julie Hyman and Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani to discuss the company's strategy to focus on the US and the impact of tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. I wonder on the Obviously, the company is celebrating the fact that you hit the largest revenues reported for the quarter. That's really good news, especially as the stated goal is to grow by 2030, and half of that to be part of the US. Talk to me about that and the shift to being a quote-unquote American company now, rather than a sort of UK-based one that we've thought of all these years. Uh, so we, you know, last May, we set this ambition of achieving 80 billion in revenues by 2030, which was almost, you know, doubling our revenues from a 2023 base. Um, and, uh, the US is our our fastest growing market. Uh, when we stack, we don't stack very highly right now, uh, in the US when when you compare pharma revenues because a lot of the pharma companies in the US have much bigger sort of revenue base, but we're growing very fast and our hope is that we'll come, you know, in in in the top five and have half of our revenue. We also set an ambition to have 20 new medicines by 2030. And, um, we already have nine of them and, uh, we announced results for another five of them. So hopefully, uh, that shows that we're on track to to achieve that goal. Well, talk to me about why the US is growing that much far faster. Is it because the dynamics of the healthcare system help boost revenues with more prescribing the the way the PBM system is set up? What are the factors that are helping you grow and are helping you stay confident about achieving that goal? So, there are a bunch of different factors. Um, I think the US is still probably the the best market in the world that rewards innovation. Uh, and we are an innovation-driven company. And so, when new therapies come, you know, we we had a product for breast cancer in her two. Uh, we announced data for another breast cancer product. But as soon as new therapy comes, um, the US market is almost the first to provide access to patients for that new therapy. Uh, secondly, physicians are really, um, you know, we go to Congresses like ASCO where there's, you know, tens of thousands of oncology physicians. They're really into, um, looking at the data and making data-driven decisions. So, again, the, you know, the physicians want the best for their patients and patients are able to get access to medicines very quickly once, you know, drug is approved and so forth in the in the innovative space. In many other markets in the world, that whole process to get approval and then get access and reimbursement just takes a very long time. So that's one reason. Um, the second reason, uh, I think particularly beneficial for oncology medicines, uh, is the part D reform. Uh, so on one hand, the part D reform that was enacted hurts us because we are responsible for paying 20% in the catastrophic phase. But from a patient standpoint, if you're a patient, um, you know, in Medicare, your out of pocket is capped at $2,000. So you can get the best therapy and have no more to pay out of pocket, right? So being in that patient population and getting the best access to medicines and the best care and have your out of pocket limited, uh, is is also great for patients. Um, so I think it's it's where physicians and patients and innovation is rewarded. And that's why it's growing faster given our portfolio is all innovative medicines. So, so let's turn then to the manufacturing base rate and the investment that you're making in the US. And I have to ask about tariffs because we even as we discussed it this morning, this new EU sort of framework agreement, it's still sort of unclear. Are pharmaceuticals coming from the EU exempt? Are they not exempt? It seems a little unclear. So how under what assumption are you operating and how do you operate in that kind of environment? Um, yeah, so you know, I would say this is not a tariff is obviously new, but how we've been thinking about our strategic manufacturing, um, is probably goes back three, four years. So post COVID, we made a strategic decision because we're such a global company that we needed to have segregated supply chains. Um, so for example, uh, in in China and in the emerging markets, we supply a lot of that product from China. Um, in the US, majority of the product is supplied from the US and and so forth in Europe. There is, uh, you know, small minority of product, handful of products actually that we still import from Europe into the US. But we do have excess capacity in the US to manufacture those products. Uh, so what we're, you know, we have 11 manufacturing sites in in the US. So our intention once the tariffs, etc. were were announced and there was talks of tariffs, uh, in the short term was just manage through inventory, so build more inventory in in the US. Um, but we've also started tech transfers for those products which we do import and that those tech transfers would be completed, you know, within a within a year or so, so that we can be fully, you know, not just have the majority, but 100% of it being manufactured in in the US. Um, this new facility that we announced, uh, was part of the plan anyway, but that's a separate has nothing to do with tariffs. It's actually based on the demand that we see potentially for our cardiovascular for new cardiovascular medicine. So, um, but you know, you're right, I think there is a little bit of confusion on when the tariffs are going to be implemented. Um, there is from what I've heard, it is a 15%, but there's also talk that that's the cap. Uh, and, uh, the administration is sort of going to wait for the 232 investigation to actually put them into effect or decide. So, uh, in either case, I think we're very well prepared and and we probably have less exposure than than many companies. Related Videos Market's 'fuel' for further P/E expansion is 'nearing empty' Nvidia's TSMC order, Eli Lilly & Novo Nordisk sink, JPMorgan & Apple card Royal Caribbean, Merck, FuboTV: Trending Tickers Why Spotify stock is sinking double digits on Q2 earnings Sign in to access your portfolio
Yahoo
8 hours ago
- Yahoo
8 liver-friendly foods to add to your diet, as majority of cancer cases preventable
Want to look after your liver better? These eight foods could help. We all know the importance of eating healthily for our heart, gut, and brain – but there are some foods that are especially beneficial for your liver health, too. Despite the liver's status as a vital organ that performs a number of important bodily functions, including removing toxins and fighting infection, it's easy to forget about looking after it. But recent statistics highlight the importance of prioritising your liver health. Experts say that three in five liver cancer cases "are linked to preventable risk factors, mostly viral hepatitis, alcohol and obesity", but have raised concerns that cases caused by alcohol and obesity will increase in the coming years. According to The Telegraph, scientists predict that, by 2050, around 21% of liver cancers will be caused by alcohol and 11% will be caused by a severe form of fatty liver disease, which occurs when excessive fat builds up in the vital organ. Last year, analysis by Cancer Research UK revealed that the number of people dying from liver cancer had almost doubled in the last 20 years. The disease is now responsible for the deaths of 58,000 people in the UK each year, twice the rate recorded in the late 1990s. Cancer Research UK said the figure is projected to continue rising by a further 10% by 2040, warning that liver cancer will have killed around 135,000 people by then. While part of the rise in deaths has been driven by a growing British population, lifestyle factors also play a major role. Katrina Brown, senior statistics manager at Cancer Research UK, told The Independent that around half of all cases are preventable. Drinking alcohol and smoking are key drivers of the increasing number of cases, as well as being overweight or obese. Brown added: "The notable thing for liver cancer is overweight and obesity is a key risk factor, and that has been steadily increasing in the UK – around two-thirds of UK adults are overweight and obese." The number of people who have died with an underlying cause of liver disease in England has also risen in recent years. According to the Department of Health and Social Care (DHSC), this figure rose to 10,127 from 9,218 in 2019, increasing further to 10,521 cases in 2021. Eating a healthy, well-balanced diet is important to protect your liver and keep it in good shape for longer. Certain foods have been found to enhance liver function, while others can help prevent or reverse liver damage, according to various studies. Here are eight liver-friendly foods to incorporate into your daily diet: 1. Leafy greens Leafy greens like spinach and kale are rich in antioxidants, vitamins and minerals, which can help protect the liver from oxidative damage. A 2019 study found that the chlorophyll in leafy greens also have detoxifying properties, which can help reduce liver toxicity. 2. Garlic While the phrase 'there's no such thing as too much garlic' may not be strictly true, eating garlic does come with health benefits. Garlic contains sulfur compounds that improve liver enzyme activity, as well as anti-inflammatory and antioxidant properties, which can reduce oxidative stress in people with non-alcoholic fatty liver disease, one study suggested. 3. Beetroot Bright red beetroot is known to help with high blood pressure, as it's rich with dietary nitrates. This root vegetable also contains betalains, a type of antioxidant, and compounds that may support liver detoxification by increasing the liver's production of detoxifying enzymes. 4. Turmeric Curcumin, the active compound in turmeric, has strong anti-inflammatory and antioxidant properties. A clinical trial published in the journal Hepatology showed that curcumin supplementation reduced liver inflammation in patients with non-alcoholic fatty liver disease. 5. Green tea A 2006 study, published in the International Journal of Molecular Medicine found that green tea extract improved liver function and reduced fat accumulation in the organ. This is believed to be thanks to the antioxidants called catechins that green tea is rich in. 6. Cruciferous vegetables Cruciferous vegetables refer to vegetables like broccoli, Brussels sprouts and cauliflower. They are rich in fibre and vitamins, as well as glucosinolates, which researchers believe stimulate the production of detoxifying enzymes in the liver and protect against oxidative damage. 7. Lentils and beans Experts often sing the praises of lentils and beans as a nutritious source of fibre and protein that is suitable for vegetarians and vegans. But that's not all – the high fibre content in lentils and beans can contribute to helping reduce liver fat accumulation and improving liver function. 8. Artichokes Researchers published a study in Phytotherapy Research that found artichoke extract, which contains cynarin, can aid in improving liver function. Cynarin is a compound known to stimulate bile production, which can helps with the detoxification process and protects liver cells. Read more about diet and nutrition: I'm a nutritionist on a budget and here's how I get my five-a-day for much less (Yahoo Life UK, 6-min read) 9 cheap, healthy and easy meal ideas with less than 6 ingredients (Yahoo Life UK, 9-min read) 5 ultra-processed foods you shouldn't stop eating (Yahoo Life UK, 5-min read)
Yahoo
8 hours ago
- Yahoo
Footballer, 27, found dead in bath days after stopping medication
A 'fit and healthy' footballer was found dead in her bath days after she stopped taking medication for epilepsy, an inquest has heard. Emily Wilcock, who played for Bury Football Club's Women Green team, died on August 21, 2023 at the age of 27. Her partner, with whom she was planning start a family, found her unresponsive in the bath at their home in Earls Close, Radcliffe. However, post-mortem examinations did not find evidence to conclude that Emily had drowned. Instead, senior coroner Joanne Kearsley, who described the case as 'very unusual and very rare', concluded that Emily died from 'natural causes' linked to epilepsy. READ MORE: 'I'm not convinced you really understand how inappropriate this was and I don't think you feel sorry about it' READ MORE: 'Amazing' RAF technician, 20, died on deployment months after devastating loss The conclusion came after Rochdale Coroner's Court heard on Monday (July 28) that Emily had stopped taking medication days earlier. Sign up to the MEN Court newsletter here The 27-year-old from Bury had been taking a 'minimal' dose of anti-epilepsy medication Lamotrigine since 2016 when her twin brother found her foaming at the mouth after sunbathing at their home before she had another suspected seizure in September of that year. She later experienced what her mum described as 'blackouts' which would be over 'within seconds'. However, despite experiencing these episodes of fainting, the inquest heard that her doctor had doubts over whether her initial diagnosis of epilepsy was correct. Sophie came off Lamotrigine in July 2023 having first discussed her medication and its impact on pregnancy with her doctor in January. Dr Nazar Sharaf, a consultant neurologist at the Northern Care Alliance, told the inquest that Emily's 'minimal' dose of Lamotrigine - which was just 50mg a day - was so small that she could stop taking the medication immediately without weaning herself off it. Within days of her coming off the medication, Emily, who was described by her sister as 'fit and healthy', was found dead in her bath. Her partner James discovered her in the bath after he returned home from work, called 999 and performed CPR on her, but to no avail. Dr Emil Salmo, a consultant pathologist based at the Royal Oldham Hospital, told the inquest that evidence of tongue biting and 'clenching of the jaw' was found during the post-mortem, but there was no evidence of 'trauma' during these examinations. He explained that Emily's lungs were 'slightly above normal' in size but said that this was not enough to conclude that she drowned. Dr Daniel du Plessis, a consultant neuropathologist, told the inquest that, after investigating other possible causes of death, including issues with her heart, but failing to obtain any positive results, he concluded that Emily died by Sudden Unexpected Death in Epilepsy. Ms Kearsley, who is the senior coroner for the Manchester North district, accepted his conclusion which he said was on a 'knife edge'. She explained that she may have reached a different conclusion had Emily stopped taking her medication a year before she died. But she told the family that, despite the timing 'tipping the balance', she could not say whether Emily's death could have been prevented had she continued taking the medication. She said: "My conclusion is that Emily died as a result of natural causes. There was nothing unnatural about her death." Addressing Emily's partner, she said: "I can see how missed she is and I know how difficult that night must have been for you. "Go and remember Emily as she was and all the good things about her." Paying tribute to Emily, her sister Sophie Wilcock, said: "She was my little sister. She was very sporty - she played football. "I was always the talkative one growing up, but she was very, very protective and willing to speak out, especially when I do things wrong. "She was so loving. So many people loved her." Following her death, Bury Football Club also paid tribute to Emily. In a statement posted on their website, the club said: "Everyone who knew Emily will know she was such a lovely person with a great personality and always had a big smile on her face."
